RX-10045

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameRX-10045
Drug Alias NameNavamepentRX-10045
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLipid modulatorsInflammation mediators inhibitors
TargetsLipid
Therapy Area/IndicationsPainInflammationCataract +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesResolvyx
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAuven TherapeuticsResolvyx Pharmaceuticals IncC.T. Development America Inc +[4] 
Active IndicationsN/A
Inactive IndicationsPainInflammationCataract +[5] 

Other Information

ATC CodeN/A
Related LinksN/A